

AMENDED CLAIMS

Claims 1-15 (cancelled).

- 5 16. (Original) A transdermal patch, comprising
a pharmaceutical composition, which comprises:
a stabilized botulinum toxin; and
an enhancing agent that facilitates transdermal administration of
the botulinum toxin in a bioactive form to a subdermal target site
10 of a human patient without being administered to the patient's
circulatory system; and
an adhesive disposed on one side of the transdermal patch to
removably secure the patch to the patient's skin.
- 15 17. (Original) The transdermal patch of claim 16, wherein the adhesive is
disposed around a depot containing the pharmaceutical
composition.
- 20 18. (Original) The transdermal patch of claim 16, further comprising a
plurality of needles extending from one side of the patch that is
applied to the skin, wherein the needles extend from the patch to
project through the stratum corneum of the skin without rupturing a
blood vessel.
- 25 19. (Original) The transdermal patch of claim 18, wherein the botulinum
toxin is provided in a depot in the patch so that pressure applied to
the patch causes botulinum toxin to be directed through the
needles and under the stratum corneum.
- 30 20. (Original) The transdermal patch of claim 16, wherein the botulinum
toxin is provided in a dry state in a plurality of wells, each of the
wells covered by a membrane that is dissolvable with a fluid, and
wherein the enhancing agent mixes with the botulinum toxin as the

membrane over a well dissolves so that the absorption of the botulinum toxin is enhanced.

21. (Original) The transdermal patch of claim 16, wherein the botulinum
5 toxin is botulinum toxin type A.

Claims 22-35 (cancelled).